Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1957 1
1958 1
1959 1
1971 1
1977 1
1978 2
1980 1
1982 1
1985 1
1986 1
1987 1
1988 1
1989 1
1991 1
1992 2
1995 1
1998 1
2000 1
2002 1
2004 1
2005 1
2008 1
2013 2
2014 1
2015 2
2016 1
2017 2
2018 1
2020 2
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL). Rummel MJ, et al. Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20. Lancet. 2013. PMID: 23433739 Clinical Trial.
Oximetry.
Josten KU. Josten KU. Br J Anaesth. 1986 Feb;58(2):248-9. doi: 10.1093/bja/58.2.248-a. Br J Anaesth. 1986. PMID: 3942681 Free article. No abstract available.
A case control investigation of COVID-19 associated mucormycosis in India.
Anand T, Mukherjee A, Satija A, Velamuri PS, Singh KJ, Das M, Josten K, Yadav PD, Sahay RR, Keche AY, Nagarkar NM, Gupta P, Himanshu D, Mistry SN, Patel JD, Rao P, Rohatgi S, Ghosh S, Hazra A, Kindo AJ, Annamalai R, Rudramurthy SM, Singh MP, Shameem M, Fatima N, Khambholja JR, Parikh S, Madkaikar M, Pradhan VD, Kataria S, Sharma P, Panda S; ICMR-Mucormycosis group. Anand T, et al. Among authors: josten k. BMC Infect Dis. 2022 Nov 16;22(1):856. doi: 10.1186/s12879-022-07844-y. BMC Infect Dis. 2022. PMID: 36384482 Free PMC article.
Satellite Epidemic of Covid-19 Associated Mucormycosis in India: A Multi-Site Observational Study.
Satija A, Anand T, Mukherjee A, Velamuri PS, Singh KJ, Das M, Josten K, Keche AY, Nagarkar NM, Gupta P, Himanshu D, Mistry SN, Patel JD, Rao P, Rohatgi S, Ghosh S, Hazra A, Kindo AJ, Annamalai R, Rudramurthy SM, Singh MP, Shameem M, Fatima N, Khambholja JR, Parikh S, Madkaikar M, Pradhan VD, Bhargava A, Mehata R, Arora RD, Tigga R, Banerjee G, Sonkar V, Malhotra HS, Kumar N, Patil R, Raut CG, Bhattacharyya K, Arthur P, Somu L, Srikanth P, Shah PB, Panda NK, Sharma D, Hasan W, Ahmed A, Bathla M, Solanki S, Doshi H, Kanani Y, Patel N, Shah Z, Tembhurne AK, Rajguru C, Sankhe LR, Chavan SS, Yadav RM, Panda S. Satija A, et al. Among authors: josten k. Mycopathologia. 2023 Oct;188(5):745-753. doi: 10.1007/s11046-023-00770-w. Epub 2023 Jul 25. Mycopathologia. 2023. PMID: 37490256
High-risk additional chromosomal abnormalities at low blast counts herald death by CML.
Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B, Fabarius A, Seifarth W, Spieß B, Wuchter P, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Burchert A, Brümmendorf TH, Hasford J, Hochhaus A, Saußele S, Baccarani M; SAKK and the German CML Study Group. Hehlmann R, et al. Leukemia. 2020 Aug;34(8):2074-2086. doi: 10.1038/s41375-020-0826-9. Epub 2020 May 7. Leukemia. 2020. PMID: 32382082 Free PMC article.
Impedance pneumography for apnea detection.
Josten KU. Josten KU. Crit Care Med. 1987 Oct;15(10):990-1. doi: 10.1097/00003246-198710000-00025. Crit Care Med. 1987. PMID: 3652720 No abstract available.
Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML.
Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B, Fabarius A, Seifarth W, Spieß B, Wuchter P, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Burchert A, Brümmendorf TH, Hasford J, Hochhaus A, Saußele S, Baccarani M; SAKK and the German CML Study Group. Hehlmann R, et al. Leukemia. 2020 Oct;34(10):2823. doi: 10.1038/s41375-020-01039-7. Leukemia. 2020. PMID: 32913312 Free PMC article.
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).
Ramalingam S, Crawford J, Chang A, Manegold C, Perez-Soler R, Douillard JY, Thatcher N, Barlesi F, Owonikoko T, Wang Y, Pultar P, Zhu J, Malik R, Giaccone G; FORTIS-M Study Investigators. Ramalingam S, et al. Ann Oncol. 2013 Nov;24(11):2875-80. doi: 10.1093/annonc/mdt371. Epub 2013 Sep 19. Ann Oncol. 2013. PMID: 24050956 Free article. Clinical Trial.
37 results